Physician profile
Vikas Sachar
NPI 1326011735
$3,303.81
in general payments reported to CMS, 2019-2025
24 companies · $726 in 2025
The $726 reported for 2025 was more than what 91% of Maternal & Fetal Medicine providers received nationally (typical 2025 total: $55.21).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $254 · 2021: $687 · 2022: $513 · 2023: $370 · 2024: $561 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,656.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $544.30 | 2019-2022 | |
| Madrigal Pharmaceuticals | $520.09 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $435.29 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $234.75 | 2022-2025 | Tremfya, Stelara |
| Redhill Biopharma INC. | $221.44 | 2020-2024 | Talicia |
| Gilead Sciences, INC. | $215.91 | 2021-2023 | Epclusa |
| Qol Medical, LLC | $178.42 | 2024 | Sucraid |
| Ironwood Pharmaceuticals, INC | $142.80 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $105.74 | 2023 | |
| Phathom Pharmaceuticals, INC. | $105.02 | 2024-2025 | Voquezna |
| Vivus LLC | $101.54 | 2019-2024 | Qsymia |
| Lilly USA, LLC | $67.92 | 2024-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $63.94 | 2023 | Cologuard Collection Kit |
| Genzyme Corporation | $58.85 | 2024 | |
| Lucid Diagnostics INC. | $57.10 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $44.82 | 2020 | |
| Currax Pharmaceuticals LLC | $44.81 | 2022-2023 | Contrave |
| Abbvie INC. | $42.08 | 2019-2024 | |
| Aimmune Therapeutics, INC. | $28.98 | 2024 | |
| Solta Medical, A Division of Bausch Health US, LLC | $23.05 | 2022 | |
| Ferring Pharmaceuticals INC. | $21.42 | 2025 | Rebyota |
| Echosens North America, INC. | $21.03 | 2024 | Fibroscan |
| Alfasigma USA, INC. | $12.94 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Sachar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.